# US 2026/0092044 A1 · Pyrimidine derivative

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0092044 A1
- Document ID: US20260092044A1
- Status: Published application
- Kind: A1
- Application number: 19/412,285
- Filed: 2025-12-08
- Published: 2026-04-02
- Earliest claimed: 2021-02-02
- Assignees: Aska Pharmaceutical Co., Ltd.
- Applicants: Aska Pharmaceutical Co., Ltd.
- Inventors: Makoto OKADA; Youichi NAKANO; Takashi NOSE; Satoshi MAEDA; Tomoaki WATANABE
- Web page: https://patentgrep.com/patent/US20260092044A1

## CPC

- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 13/10: of the bladder
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A compound of the formula (I) or a salt thereof (R represents methyl group or fluorine atom) having an mPGES-1 inhibitory activity and useful as an active ingredient of a medicament for prophylactic and/or therapeutic treatment of such diseases as inflammation, pain, or rheumatism.

## Claims

### Claim 1

A method for preventing and/or treating inflammation, pain, rheumatism, osteoarthritis, pyrexia, Alzheimer's disease, multiple sclerosis, arteriosclerosis, ocular hypertension, ischemic retinopathy systemic scleroderma, malignant tumor, overactive bladder, bladder outlet obstruction associated with benign prostatic hyperplasia, nocturia, urinary incontinence, neurogenic bladder, interstitial cystitis, bladder pain syndrome, urinary calculus, benign prostatic hyperplasia, or a disease for which suppression of the PGE2 production exhibits efficacy which comprises administrating an effective amount of a compound represented by the following general formula (I):
in the formula, R represents methyl group or fluorine atom, or a physiologically acceptable salt thereof to a mammal including human.

### Claim 2 (depends on 1)

The method according to claim 1, wherein R is methyl group.
